Research programme: anti-cd38 antibodies - ProMIS Neurosciences/Trellis Bioscience

Drug Profile

Research programme: anti-cd38 antibodies - ProMIS Neurosciences/Trellis Bioscience

Latest Information Update: 23 Jul 2015

Price : $50

At a glance

  • Originator Amorfix Life Sciences; Trellis Bioscience
  • Developer ProMIS Neurosciences; Trellis Bioscience
  • Class Monoclonal antibodies
  • Mechanism of Action CD38 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies

Most Recent Events

  • 14 Jul 2015 Amorfix Life Sciences is now called ProMIS Neurosciences
  • 18 Mar 2014 Early research in Haematological malignancies in Canada (Parenteral)
  • 18 Mar 2014 Early research in Haematological malignancies in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top